One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine (Plaquenil), a chloroquine derivative. It is used to treat many diseases including malaria, rheumatoid arthritis and systemic lupus erythematosus. Chloroquine proguanil combination Plaquenil and ibuprophen Cardiomyopathy caused by plaquenil Hydroxychloroquine image Apr 17, 2017 The quinine family of drugs has been used for a variety of conditions, and Hydroxychloroquine Sulphate Plaquenil is a valuable drug for the treatment of certain auto-immune collagen-vascular disease processes. Rheumatoid Arthritis RA and Systemic Lupus Erithematosus SLE are conditions for which Hydroxychloroquine has been found to be of help. The American Academy of Ophthalmology released an updated set of screening recommendations for hydroxychloroquine Plaquenil and chloroquine to account for the many studies that have shown the effects of these medications on the retina 1. It succinctly makes the case for screening, and Contrary to the 2011 recommendations, age, liver disease, and obesity are not well correlated with the risk of retinopathy. 5 The major risk factors are dose and duration, underlying maculopathy, renal disease, and tamoxifen use. 3 The new recommendations reinforce advice in the Invited Commentary by Kim to look beyond the macula when screening. It is imperative that patients and physicians are aware of and watch for this drug’s ocular side effects. Retinal toxicity from hydroxychloroquine is rare, but even if the medication is discontinued, vision loss may be irreversible and may continue to progress. Plaquenil retina screening guidelines Recommendations on Screening for Chloroquine and., Hydroxychloroquine And Chloroquine Screening 2016 AAO. Chloroquine classChloroquine phosphate autophagyTreatment of discoid lupus erythematosus with chloroquine Mar 10, 2017 Hydroxychloroquine retinal toxicity is far more common than previously considered; an overall prevalence of 7.5% was identified in patients taking HCQ for greater than 5 years, rising to almost 20. Hydroxychloroquine retinopathy Eye. Update on Screening Recommendations for Hydroxychloroquine.. Protecting your eyesight when taking Plaquenil Lupus.. Screening guidelines were updated this year, with some pertinent changes for our profession to note. Cumulative dose is no longer a risk factor, but more of a tool in the screening of our patients. Some patients, toxicity may first present as pericentral retinopathy and thus requires screening outside the macula. We assume chloroquine retinopathy follows a similar course as hydroxychloroquine retinopathy and so these guidelines also apply to patients taking chloroquine therapy. And screening tests, but that screening begins after one year of therapy for all patients on chloroquine. Screening may be best incorporated into the hospital eye service via virtual clinics. The results of screening should be communicated back to the prescribing doctor, patient and GP as normal, possible or definite hydroxychloroquine retinopathy.